Publications by authors named "Mark S Shaefer"

Claim this Profile
P
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Vasiliki Chounta, Edgar T Overton, Anthony Mills, Susan Swindells, Paul D Benn, Mark S Shaefer

Patient· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort.
Karam C Mounzer, Jennifer S Fusco, Ricky K Hsu, Laurence Brunet, Vani Vannappagari, Mark S Shaefer

AIDS Patient Care STDS· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment.
Karam Mounzer, Laurence Brunet, Christina M Wyatt, Jennifer S Fusco, Vani Vannappagari, Mark S Shaefer

AIDS· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
Lisa L Ross, A Sarah Walker, Yu Lou, Allan R Tenorio, Diana M Gibb, Mark S Shaefer

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Kevin Robertson, Paul Maruff, Lisa L Ross, David Wohl, Catherine B Small, Mark S Shaefer

J Neurovirol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
Chris M Stainsby, Teodora M Perger, Vani Vannappagari, Karam C Mounzer, Ricky K Hsu, Mark S Shaefer

Pharmacotherapy· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA observational database: a cohort study.
Karam Mounzer, Ricky Hsu, Jennifer S Fusco, Laurence Brunet, Cassidy E Henegar, Mark S Shaefer

AIDS Res Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.
Lisa L Ross, Denise Shortino, Mark S Shaefer

AIDS Res Hum Retroviruses· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
Catherine Butkus Small, David A Margolis, Mark S Shaefer, Lisa L Ross

BMC Infect Dis· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.
Kathleen E Squires, Benjamin Young, Lizette Santiago, Robin H Dretler, Sharon L Walmsley, Mark S Shaefer

HIV AIDS (Auckl)· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
Benjamin Young, Kathleen E Squires, Karen Tashima, Keith Henry, Stefan Schneider, Mark S Shaefer

HIV Clin Trials· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing.
Lisa L Ross, Joseph Horton, Samiul Hasan, James R Brown, Daniel Murphy, Mark S Shaefer

PLoS One· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
David A Wohl, Laveeza Bhatti, Catherine B Small, Howard Edelstein, Henry H Zhao, Mark S Shaefer

PLoS One· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Benjamin Young, Kathleen E Squires, Lisa L Ross, Lizette Santiago, Louis M Sloan, Mark S Shaefer

AIDS Res Hum Retroviruses· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
Kathleen E Squires, Benjamin Young, Edwin DeJesus, Nicholaos Bellos, Daniel Murphy, Mark S Shaefer

HIV Clin Trials· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Kathleen E Squires, Benjamin Young, Edwin Dejesus, Nicholaos Bellos, Daniel Murphy, Mark S Shaefer

AIDS· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
Kathleen E Squires, Benjamin Young, Edwin DeJesus, Nicholas Bellos, Daniel Murphy, Mark S Shaefer

HIV Clin Trials· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Kimberly Y Smith, Parul Patel, Derek Fine, Nicholaos Bellos, Louis Sloan, Mark S Shaefer

AIDS· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).
Princy N Kumar, Patricia Salvato, Anthony LaMarca, Edwin DeJesus, Parul Patel, Mark S Shaefer

AIDS Res Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
Calvin J Cohen, Marshall Kubota, Philip S Brachman, William B Harley, Stefan Schneider, Mark S Shaefer

Pharmacotherapy· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Peter Ruane, Joseph Lang, Edwin DeJesus, Daniel S Berger, Robin Dretler, Mark S Shaefer

HIV Clin Trials· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
John A Bartlett, Judy Johnson, Gisela Herrera, Nestor Sosa, Alan Rodriguez, Mark S Shaefer

J Acquir Immune Defic Syndr· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Joel E Gallant, Allan E Rodriguez, Winkler G Weinberg, Benjamin Young, Daniel S Berger, Mark S Shaefer

J Infect Dis· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen.
Mark S Shaefer

Ann Pharmacother· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus.
Peter J Ruane, Gary J Richmond, Edwin DeJesus, Christina E Hill-Zabala, Susan C Danehower, Mark S Shaefer

Pharmacotherapy· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis